Calcium antagonists and cardiovascular risk in diabetes.
Recent trials have linked calcium antagonists with adverse cardiovascular events in hypertensive patients with diabetes. A closer examination of these trials (in particular the Appropriate Blood Pressure Control in Diabetes [ABCD] trial and the Fosinopril Versus Amlodipine Cardiovascular Events Trial [FACET]) reveals a lack of data from which to draw conclusions of harm. In fact, based on the results of these trials and the recent Hypertension Optimal Treatment (HOT) Trial, one may conclude that the combination of a calcium antagonist with an ACE inhibitor is a rational therapeutic choice in patients with coexisting hypertension and diabetes.
Parving
H H
HH
Steno Diabetes Center, Gentofte, Denmark.
D017311:Amlodipine / Q000009:adverse effects; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000009:adverse effects; D000959:Antihypertensive Agents / Q000009:adverse effects*; D002121:Calcium Channel Blockers / Q000009:adverse effects*; D002318:Cardiovascular Diseases / Q000139:chemically induced*; D048909:Diabetes Complications; D004359:Drug Therapy, Combination; D005060:Europe; D017328:Fosinopril / Q000009:adverse effects; D006801:Humans; D006973:Hypertension / Q000150:complications / Q000188:drug therapy; D015337:Multicenter Studies as Topic; D016032:Randomized Controlled Trials as Topic
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D002121:Calcium Channel Blockers; D017311:Amlodipine; D017328:Fosinopril